Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target

Benzinga Newsdesk www.benzinga.com Negative 44.3%

Neg 44.3% Neu 0% Pos 0%

Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.